MBX Biosciences (MBX) Total Liabilities (2023 - 2026)

MBX Biosciences (MBX) has 4 years of Total Liabilities data on file, last reported at $14.9 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 42.28% year-over-year to $14.9 million; the trailing twelve-month figure through Mar 2026 stood at $14.9 million (up 42.28% YoY), and the FY2025 full-year result was $15.9 million, up 43.52% from the prior year.
• Total Liabilities declined to $14.9 million in Q1 2026, from $15.9 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $15.9 million in Q4 2025 to a low of $4.3 million in Q4 2023.
• A 4-year average of $11.6 million and a median of $11.7 million in 2024 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities jumped 158.52% in 2024 and increased 13.65% in 2025, its largest moves.
• Tracing MBX's Total Liabilities over 4 years: stood at $4.3 million in 2023, then surged by 158.52% to $11.1 million in 2024, then jumped by 43.52% to $15.9 million in 2025, then decreased by 6.13% to $14.9 million in 2026.
• Business Quant data shows MBX's Total Liabilities at $14.9 million in Q1 2026, $15.9 million in Q4 2025, and $12.5 million in Q3 2025.